TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07703436: Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

Sponsor: Nuvation Bio Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,626,800

Rescue Site Savings

+$1,062,400

Unlock Full NCT07703436 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07703436 Rescue Dossier →